Clinical Trial Update: Extracorporeal Photopheresis and Mogamulizumab for the Treatment of Erythrodermic Cutaneous T Cell Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the combination of extracorporeal photopheresis and mogamulizumab for erythrodermic cutaneous T-cell lymphoma, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous T-cell Lymphoma
• Folliculotropic Mycosis Fungoides
• Mycosis Fungoides
• Sézary Syndrome

Drugs mentioned

• Extracorporeal Photopheresis
• Poteligeo (mogamulizumab)

Snippet

Sponsor: City of Hope Medical Center | Conditions: Folliculotropic Mycosis Fungoides, Primary Cutaneous T-Cell Non-Hodgkin Lymphoma | Phase 2 | Status: RECRUITING